TLDR Needham cut its price target on HOOD from $100 to $90, maintaining a Buy rating Compass Point slashed its target from $127 to $108, also keeping a Buy ratingTLDR Needham cut its price target on HOOD from $100 to $90, maintaining a Buy rating Compass Point slashed its target from $127 to $108, also keeping a Buy rating

Robinhood (HOOD) Stock Hits Turbulence After Three Price Target Cuts in Two Days

2026/04/03 00:08
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • Needham cut its price target on HOOD from $100 to $90, maintaining a Buy rating
  • Compass Point slashed its target from $127 to $108, also keeping a Buy rating
  • March metrics showed slowed equity, options, and crypto trading volumes
  • HOOD is down 52% over the past six months and 38% year-to-date
  • Robinhood’s banking division has surpassed $1.5 billion in deposits

Robinhood has had a rough week. Multiple analysts have trimmed their price targets on the stock after the company released softer-than-expected March trading metrics.


HOOD Stock Card
Robinhood Markets, Inc., HOOD

Needham analyst John Todaro cut his price target from $100 to $90 on Wednesday, while holding his Buy rating. He pointed to slower growth across nearly every part of the platform.

The March data, released on March 30, showed equity notional trading volumes of around $196 billion. Options contracts traded came in at 187 million, and crypto notional trading volumes hit $16 billion.

Todaro lowered his equities and options estimates for Q1 2026 but kept crypto volume projections flat, saying declines there were already baked into prior estimates. He also cut revenue forecasts for 2026 and 2027, driven by lower expected trading volumes and reduced net interest revenues.

The new $90 target is based on 27 times Needham’s discounted fiscal year 2027 EV/EBITDA estimate.

This followed a move by Wolfe Research analyst Steven Chubak just a day earlier, who cut his price target from $115 to $81 — a drop of roughly 30%. That revision came after crypto transaction revenue fell, compounded by broader weakness in the crypto market.

Compass Point Also Trims Forecast

Compass Point analyst Ed Engel also reduced his price target on Wednesday, cutting from $127 to $108 while keeping a Buy rating. His models put Q1 revenue 9% below consensus, with misses across all three business segments.

Engel noted that retail trading historically slows after five to six consecutive months of choppy markets, and that most retail-favorite stocks are broadly lower since early October.

He drew a comparison to April 2025, when Wall Street was cutting forecasts ahead of Liberation Day. Engel suggested that a market recovery could make Robinhood a key beneficiary given the 2026 IPO pipeline.

HOOD stock has now fallen 52% over the past six months and sits 46% below its 52-week high of $153.86. The stock carries a P/E ratio of 34.14 and a market cap of $63.1 billion. InvestingPro flags the stock as overvalued at current levels.

Banking Division Offers a Bright Spot

Not everything is pointing down. Robinhood’s banking division has crossed $1.5 billion in deposits, with nearly 100,000 funded customers — a roughly 50% increase in deposits over a recent period.

Bernstein SocGen Group cut its price target from $160 to $130, but kept an Outperform rating. The firm still projects 25% earnings per share growth by 2026 and a 30% revenue CAGR from 2025 to 2027.

Jefferies initiated coverage with a Buy rating and an $88 price target, citing potential from increased global retail participation and a broad product set.

On TipRanks, HOOD holds a Strong Buy consensus based on 15 Buy and 2 Hold ratings, with a consensus price target of $117.33 — implying roughly 67% upside from current levels. The highest price target on the stock stands at $147.

Full Q1 results are expected in May.

The post Robinhood (HOOD) Stock Hits Turbulence After Three Price Target Cuts in Two Days appeared first on CoinCentral.

Market Opportunity
SIX Logo
SIX Price(SIX)
$0.00795
$0.00795$0.00795
0.00%
USD
SIX (SIX) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage